Abstract Background Mesenchymal precursor cells (MPCs) are allogeneic, immunoselected
cells with anti-inflammatory properties that could improve outcomes in heart failure with …

Rationale: Allogeneic mesenchymal precursor cells (MPCs) have been effective in large
animal models of ischemic and nonischemic heart failure (HF). Objective: To evaluate the …

Advanced heart failure (HF) is a progressive disease characterized by recurrent
hospitalizations and high risk of mortality. Indeed, outcomes in late stages of HF …

Objectives: This study sought to evaluate the feasibility and safety of autologous bone
marrow–derived and cardiogenically oriented mesenchymal stem cell therapy and to probe …

Background: Although human mesenchymal stem cells (hMSCs) have been tested in
ischemic cardiomyopathy, few studies exist in chronic nonischemic dilated cardiomyopathy …

Objectives: This study set out to evaluate the safety and efficacy of allogeneic bone marrow
mesenchymal precursor cells (MPC) delivered by multisegmental, transendocardial …

Rationale: Potential benefits of mesenchymal stem cell (MSC) therapy in heart failure may
be related to paracrine properties and systemic effects, including anti-inflammatory activities …

Background Optimal cell type as cell-based therapies for heart failure (HF) remains unclear.
We sought to compare the safety and efficacy of direct intramyocardial transplantation of …

Rationale: Cell dose and concentration play crucial roles in phenotypic responses to cell-
based therapy for heart failure. Objective: To compare the safety and efficacy of 2 doses of …

Despite significant advances in medical and surgical management of heart failure, mostly of
ischaemic origin, the mortality and morbidity associated with it continue to be high …